{"id":1488,"date":"2015-05-26T15:28:11","date_gmt":"2015-05-26T19:28:11","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=1488"},"modified":"2017-03-31T16:18:25","modified_gmt":"2017-03-31T20:18:25","slug":"treating-gc-in-the-face-of-dwindling-antibiotic-options-1","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2015\/05\/26\/1488\/treating-gc-in-the-face-of-dwindling-antibiotic-options-1\/","title":{"rendered":"Treating GC in the Face of Dwindling Antibiotic Options \u2013 (1)"},"content":{"rendered":"

\"\"<\/a><\/p>\n

Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg\u00a0[1]<\/a>. In the US, CDC has opted for combination treatment with ceftriaxone plus azithromycin, with several alternatives, one of which includes cefixime at the more conventional dose of 400 mg. It made cefixime a 2nd<\/sup> line option mainly because of treatment failures abroad and a rising resistance trend for cefixime between 2006 and 2011 when MICs of 0.25 \u03bcg\/mL were recorded in 1.3% of isolates. Of interest,\u00a0there are\u00a018 isolates with MIC of 0.5 \u03bcg\/mL\u00a0and 1 isolate with an MIC of 1.0 \u03bcg\/mL\u00a0in the GISP database\u00a0[2]<\/a>.<\/p>\n

Less known is the fact that since 2011 the feared increase in cefixime resistance actually reversed: in 2013, only 0.4% of isolates had MICs in the 0.25 \u03bcg\/mL category (down from 1.3% in 2011) and there also were significantly fewer isolates with MICs of\u00a00.5 \u03bcg\/mL. \u00a0So, for practical purposes, cefixime at a single dose of 400 mg PO should still work just as well as before the Guideline change.<\/p>\n

That is good news but should not be interpreted to mean that our treatment options for GC are what they were.<\/p>\n

Moran et al. from CDC published an article in 1995 in which they mention that \u201cthirty regimens comprising 21 antimicrobial drugs have been shown to be highly effective for rectal and urogenital infections; the agents involved are cefixime, cefodizime, cefotaxime, cefoxitin, ceftizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, ciprofloxacin, fleroxacin, norfloxacin, ofloxacin, pefloxacin, temafloxacin, azithromycin, aztreonam, netilmicin, rifampin plus erythromycin stearate, sisomicin, and spectinomycin<\/em>.\u201d[3]<\/a><\/a><\/p>\n

At first blush it seems we have used up a good number of drugs in the past 20 years but that is not really the case. Many quinolones on the list have become resistant to GC in lock-step with ciprofloxacin. Temafloxacin is gone because of a unique side effect (hemorrhagic uremic syndrome). Spectinomycin, a very atypical aminoglycoside, is no longer available in the US (abandoned by Pfizer around 2007) but still has adequate activity and could be resurrected if need be. Siso- and netilmycin have never seen much use in the US but the recent CDC Guideline mentions that gentamicin at a single IV dose of 240 mg may be an option for special cases. Of the macrolide class, erythromycin is out but azithromycin at the 1 g PO dose (in conjunction with ceftriaxone IM) or as a single drug regimen (2 gm PO of the extended-release form) has retained a solid place in the treatment option line-up.<\/p>\n

\"from:<\/a>
from: Urban Dictionary<\/figcaption><\/figure>\n

Many of\u00a0the beta-lactams have been decimated, however ceftriaxone experienced\u00a0a marvelous come-back. Why has this drug beaten the odds and remains as active as ever?\u00a0 Well, if you look at the CDC data you get a bit concerned: in 2013, an increase in high-MIC level pathogens (MIC = 2) can be observed in 0.4% of isolates, a 3-4 fold increase over previous years. An ominous fact or just a blip?<\/p>\n

Who knows. A single number does not make a trend, but Dr. Neisser’s\u00a0gonococcus is a wily organism. Hence, it is good to see that FDA has bestowed QIDP status on several drugs now in development specifically for GC. In an upcoming blog I will discuss the 3 candidates: solithromycin (CEM-101), AZ-0914, and delafloxacin. Stay tuned.<\/p>\n

NOTE: Updated STD Guidelines were published in MMWR June 5, 2015,
\nwith the following recommendations:<\/strong><\/span>
\n\"GC<\/a>\"GC<\/p>\n

Abbreviations:
\n<\/strong>GISP = Gonococcal\u00a0Isolates Surveillance Project<\/p>\n

References:
\n<\/strong>[1]<\/a> http:\/\/www.phac-aspc.gc.ca\/std-mts\/sti-its\/cgsti-ldcits\/section-5-6-eng.php#toc361210467
\n[2]<\/a> http:\/\/www.cdc.gov\/std\/gisp2013\/table1.htm
\n[3]<\/a> J Moran\u00a0 Clin Infect Dis 1995;20 (Suppl 1): S47<\/p>\n","protected":false},"excerpt":{"rendered":"

Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg\u00a0[1]. In the US, CDC has opted for combination treatment with ceftriaxone Continue reading Treating GC in the Face of Dwindling Antibiotic Options \u2013 (1)<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[140,19,227,3],"tags":[176,403,1011,211,336,722,639,265,994,995,821,999,998,816,1000,1010,517,42,996,236,221,1002,509,766,1015,1014,814,223,997,813,1016,1007,1003,916,1006,1004,655,1013,827,1008,468,815,1012,993,1005,1009,1001,212],"class_list":["post-1488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interesting_facts","category-qidp_antibiotic","category-recent_literature","category-the_news","tag-aminoglycoside","tag-antibiotic-blog","tag-az-0914","tag-azithromycin","tag-aztreonam","tag-beta-lactam","tag-cdc","tag-cefixime","tag-cefodizime","tag-cefotaxime","tag-cefoxitin","tag-ceftizox","tag-ceftizoxime","tag-ceftriaxone","tag-cefuroxime","tag-cem-101","tag-cipro","tag-ciprofloxacin","tag-claforan","tag-delafloxacin","tag-erythromycin","tag-fleroxacin","tag-fluoroquinolones","tag-gentamicin","tag-gisp-database","tag-gonococcal-resistance","tag-gonorrhea","tag-macrolide","tag-mefoxitin","tag-n-gonorrhoeae","tag-neisser","tag-netilmicin","tag-norfloxacin","tag-ofloxacin","tag-omniflox","tag-pefloxacin","tag-pfizer","tag-public-health-canada","tag-rocephin","tag-sisomicin","tag-solithromycin","tag-spectinomycin","tag-std-recommendations","tag-suprax","tag-temafloxacin","tag-trobicin","tag-zinacef","tag-zithromax"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/05\/GC-slider1.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-o0","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1254,"url":"https:\/\/allphasepharma.com\/dir\/2015\/02\/02\/1254\/a-go-no-go-decision-delafloxacin-stumbles-in-gonorrhea-study\/","url_meta":{"origin":1488,"position":0},"title":"A GO \/ NO GO decision:\u00a0 Delafloxacin Stumbles in Gonorrhea Study","author":"Harald","date":"February 2, 2015","format":false,"excerpt":"The treatment history of N. gonorrhoeae makes for fascinating reading.\u00a0 This organism has always been able to keep the upper hand in the war of bug versus drug.\u00a0 Once susceptible to sulfa drugs, to penicillin, tetracyclines and fluoroquinolones, it sequentially become resistant in the matter of a decade to every\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"mic-2","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/mic-2.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":3238,"url":"https:\/\/allphasepharma.com\/dir\/2017\/03\/21\/3238\/gc-therapy-shooting-stars\/","url_meta":{"origin":1488,"position":1},"title":"GC Therapy – \u00a0Shooting for the Stars","author":"Harald","date":"March 21, 2017","format":false,"excerpt":"Besides ceftriaxone (CTRIAX), cefixime and spectinomycin we have no other highly effective single-dose treatment regimens for urogenital GC. Failures of all 3 drugs have been described but remain rare, can be overcome with higher doses of CTRIAX (1 g instead of 250 mg IM) or with azithromycin combination therapy. Worse\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/GC-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/GC-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/GC-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1561,"url":"https:\/\/allphasepharma.com\/dir\/2015\/06\/17\/1561\/treating-gc-in-the-face-of-dwindling-antibiotic-options-2\/","url_meta":{"origin":1488,"position":2},"title":"Treating GC in the Face of Dwindling Antibiotic Options \u2013 (2)","author":"Harald","date":"June 17, 2015","format":false,"excerpt":"For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let\u2019s take Melinta\u2019s statement\u00a0[1] at face value according to which the single 900 mg dose of delafloxacin failed because of \"insufficient efficacy\". So, what then determines efficacy? \u00a0Delafloxacin's MIC90 was\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"GC MIC formula","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/GC-MIC-formula.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":3257,"url":"https:\/\/allphasepharma.com\/dir\/2017\/03\/29\/3257\/fake-news-spectinomycin\/","url_meta":{"origin":1488,"position":3},"title":"The CDC and Spectinomycin","author":"Harald","date":"March 29, 2017","format":false,"excerpt":"Pfizer discontinued US distribution of spectinomycin (Trobicin\u00ae) in November 2005; remaining inventory expired in May 2006\u00a0[1]. Nonetheless, at the FDA website we still find a Package Insert for Trobicin updated as late as Aug 2012, a thin 6-page leaflet which seems to have survived from the 80s. The drug is\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Spectino-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Spectino-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Spectino-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":521,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/06\/521\/aeromonas-salmonicida-trouble-for-aquaculture-with-drug-resistance\/","url_meta":{"origin":1488,"position":4},"title":"Aeromonas salmonicida: Trouble for Aquaculture with Drug Resistance","author":"Harald","date":"July 6, 2014","format":false,"excerpt":"Aeromonas salmonicida causes furunculosis in salmon hatcheries and in freshwater fish.\u00a0 The organism has several recognized virulence mechanisms including the T3SS\u00a0[1].\u00a0 A. salmonicida\u00a0has become resistant to penicillin, tetracycline and erythromycin.\u00a0 It remains susceptible to chloramphenicol and aminoglycoside according to a publication from Romania [2] but another reference describes it as\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Salmon","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/Salmon.jpe","width":350,"height":200},"classes":[]},{"id":2480,"url":"https:\/\/allphasepharma.com\/dir\/2016\/05\/12\/2480\/azd-0914-a-new-broad-spectrum-narrow-development-path-drug\/","url_meta":{"origin":1488,"position":5},"title":"AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug","author":"Harald","date":"May 12, 2016","format":false,"excerpt":"At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers\u00a0mention a peculiar MoA for this gyrase\/topoisomerase\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"gonorrhea - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/05\/gonorrhea-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/05\/gonorrhea-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/05\/gonorrhea-slider.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=1488"}],"version-history":[{"count":12,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1488\/revisions"}],"predecessor-version":[{"id":3279,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1488\/revisions\/3279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/1493"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=1488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=1488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=1488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}